Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Anti-HBV activity of the HBV capsid assembly modulator JNJ-56136379 across full-length genotype A-H clinical isolates and core site-directed mutants in vitro.

The Journal of antimicrobial chemotherapy - 1 Sept 2020

Verbinnen Thierry, Tan Ying, Wang Gengyan, Dehertogh Pascale, Vergauwen Karen, Neefs Jean-Marc, Jacoby Edgar, Lenz Oliver, Berke Jan Martin

Abstract excerpt

OBJECTIVES: To characterize antiviral activity of the capsid assembly modulator (CAM-N) JNJ-56136379 against HBV genotypes and variants carrying amino acid substitutions in the core protein. METHODS: Anti-HBV activity of JNJ-56136379 was investigated against a diverse panel of 53 HBV clinical isolates (genotypes A-H). The impact of core amino acid substitutions using site-directed mutants (SDMs) was assessed in a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Capsid

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Capsid Proteins

Share to DNA, Viral

Share to Genotype

Share to Hepatitis B, Chronic

Share to Hepatitis B e Antigens

Share to Hepatitis B virus

Source

Identifiers

PMID: 32417895
DOI: 10.1093/jac/dkaa179

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Anti-HBV activity of the HBV capsid assembly modulator JNJ-56136379 across full-length genotype A-H clinical isolates and core site-directed mutants in vitro.PMID 32417895Read ↗

Antiviral profiling of the capsid assembly modulator BAY41-4109 on full-length HBV genotype A-H clinical isolates and core site-directed mutants in vitro.Semantic proximity Read ↗

Preclinical and clinical antiviral characterization of AB-836, a potent capsid assembly modulator against hepatitis B virus.Semantic proximity Read ↗

Novel non-HAP class A HBV capsid assembly modulators have distinct in vitro and in vivo profilesSemantic proximity Read ↗

Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV).Semantic proximity Read ↗

Assembly Properties of Hepatitis B Virus Core Protein Mutants Correlate with Their Resistance to Assembly-Directed Antivirals.Semantic proximity Read ↗

Preclinical Profile and Characterization of the Hepatitis B Virus Core Protein Inhibitor ABI-H0731Semantic proximity Read ↗

A multiscale model of the action of a capsid assembly modulator for the treatment of chronic hepatitis BSemantic proximity Read ↗

Influences on viral replication and sensitivity to GLS4, a HAP compound, of naturally occurring T109/V124 mutations in hepatitis B virus core protein.Semantic proximity Read ↗

Structural and Mechanistic Bases for Resistance of the M66I Capsid Variant to LenacapavirSemantic proximity Read ↗

Design, synthesis and profiling of highly potent antivirals targeting emerging drug-resistant HIV-1 variantsSemantic proximity Read ↗

Mechanistic insights into CAM-induced disruption of HBV capsids revealed by all-atom MD simulationsSemantic proximity Read ↗

Treatment of Chronic Hepatitis B Virus Infection Using Small Molecule Modulators of Nucleocapsid Assembly: Recent Advances and PerspectivesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.